Clinical Drug Investigation

, Volume 25, Issue 12, pp 803–809 | Cite as

Famciclovir for the Management of Genital Herpes Simplex in Patients with Inadequate Response to Aciclovir or Valaciclovir

Short Communication


Herpes Simplex Virus Immunocompromised Patient Genital Herpes Immunocompetent Patient Herpes Simplex Virus Infection 



This study was supported by a research grant provided by Novartis. Dr Sacks had no potential conflicts of interest that are directly relevant to the contents of this article. Dr Aoki has received payments from Novartis for participation in their clinical trials and for speaking at symposia sponsored by Novartis.

We thank all the physicians who were involved with the study, particularly the principal investigators: Mark O’Loveless (Portland, OR); Stephen Sacks (Vancouver, BC); Javier Morales-Ramirez (San Juan, Puerto Rico); Adelaide A. Herbert (Houston, TX); George Harb (Ft Lauderdale, FL); Jerry C. Stern (New York); Terri Warren (Portland, OR).


  1. 1.
    Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral aciclovir. JAMA 1984; 251: 2103–7PubMedCrossRefGoogle Scholar
  2. 2.
    de Miranda P, Blum MR. Pharmacokinetics of aciclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12Suppl. B: 29–37Google Scholar
  3. 3.
    Douglas JM, Critchlon C, Benedetti J. A double-blind study of oral acyclovir for the suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310: 1551–6PubMedCrossRefGoogle Scholar
  4. 4.
    Kinghorn GR. Long-term suppression with oral aciclovir of recurrent herpes simplex virus infections in otherwise healthy patients. Am J Med 1988; 85Suppl. 2A: 26–9PubMedGoogle Scholar
  5. 5.
    Boyd MR, Safrin S, Kern ER. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir Chem Chemother 1993; 4Suppl. 1: 3–11Google Scholar
  6. 6.
    Boyd MR, Bacon TH, Sutton D, et al. Anti-herpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987; 31: 1238–42PubMedCrossRefGoogle Scholar
  7. 7.
    Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3hydroxymethyl but-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989; 33: 223–9CrossRefGoogle Scholar
  8. 8.
    Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993; 4Suppl. 1: 47–55Google Scholar
  9. 9.
    Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750mg to healthy volunteers. J Antimicrob Chemother 1994; 33: 119–27PubMedCrossRefGoogle Scholar
  10. 10.
    Vere Hodge RA, Darlison SJ, Earnshaw DL, et al. Use of isotopically chiral [4′-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase. Chirality 1993; 5: 583–8CrossRefGoogle Scholar
  11. 11.
    Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996; 276: 44–9PubMedCrossRefGoogle Scholar
  12. 12.
    Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-group, randomized, double-blind clinical trial. Br J Dermatol 2001; 144: 818–24PubMedCrossRefGoogle Scholar
  13. 13.
    Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS 2000; 14: 1211–7PubMedCrossRefGoogle Scholar
  14. 14.
    Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998; 280: 887–92PubMedCrossRefGoogle Scholar
  15. 15.
    Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997; 157: 343–9PubMedCrossRefGoogle Scholar
  16. 16.
    Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann Intern Med 1998; 128: 21–8PubMedGoogle Scholar
  17. 17.
    Kost RG, Hill EL, Tigges M, et al. Recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993; 329: 1777–82PubMedCrossRefGoogle Scholar
  18. 18.
    Mouly F, Baccard M, Scieux C, et al. Chronic recurrent acyclovir-resistant genital herpes in an immunocompetent patient [letter]. Dermatology 1995; 190: 177PubMedCrossRefGoogle Scholar
  19. 19.
    Setter SM, Hill EL, Kern ER, et al. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J Infect Dis 1998; 1777: 543–50CrossRefGoogle Scholar
  20. 20.
    Kriesel, JD, Spruance L, Parker JN, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192: 156–61PubMedCrossRefGoogle Scholar
  21. 21.
    Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 1990; 112: 416–22PubMedGoogle Scholar
  22. 22.
    Crumpacker CS, Schnipper LE, Marlowe SI, et al. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 1982; 306: 343–6PubMedCrossRefGoogle Scholar
  23. 23.
    Burns WH, Saral R, Santos GW, et al. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet 1982; 1(8269): 421–3PubMedCrossRefGoogle Scholar
  24. 24.
    Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple course of treatment with acyclovir. J Infect Dis 1983; 148: 1077–82PubMedCrossRefGoogle Scholar
  25. 25.
    Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293–6PubMedCrossRefGoogle Scholar
  26. 26.
    Chilukuri S, Rosen T. Management of aciclovir-resistant herpes simplex virus. Dermatol Clin 2003; 21: 311–30PubMedGoogle Scholar
  27. 27.
    Engel JP, Englund JA, Fletcher CV, et al. Treatment of resistant-herpes simplex virus with continuous-infusion aciclovir. JAMA 1990. 263(12): 1662–4PubMedCrossRefGoogle Scholar
  28. 28.
    Fletcher CV, Englund JA, Bean B, et al. Continuous infusion of high-dose aciclovir for serious herpesvirus infections. Antimicrob Agents Chemother 1989; 33: 1375–8PubMedCrossRefGoogle Scholar
  29. 29.
    Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for aciclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325: 551–5PubMedCrossRefGoogle Scholar
  30. 30.
    Stewart JA, Reef SE, Pellett PE, et al. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21Suppl. 1: S114–20PubMedCrossRefGoogle Scholar
  31. 31.
    Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster; a randomised aciclovir controlled study. Br J Ophthalmol 2001; 85: 576–81PubMedCrossRefGoogle Scholar
  32. 32.
    Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valaciclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863–9PubMedCrossRefGoogle Scholar
  33. 33.
    Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrobial Agents Chemother 1994; 38: 2454–7CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of Pharmacology and Therapeutics, Faculty of MedicineThe University of British ColumbiaVancouverCanada
  2. 2.Department of Medical Microbiology, Faculty of MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations